Sanofi and Regeneron Report Positive Phase 3 Results for Dupixent in Bullous Pemphigoid

Sanofi and Regeneron today announced positive results from the Phase 3 LIBERTY-BP ADEPT trial evaluating Dupixent (dupilumab) in patients with bullous pemphigoid (BP). The trial met its primary endpoint, demonstrating a significantly higher rate of sustained disease remission compared to placebo at week 36.